Product Images Isosorbide Mononitrate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Isosorbide Mononitrate NDC 70518-2122 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Isosorbide Mononitrate 30mg 70518 2122 01

Isosorbide Mononitrate 30mg 70518 2122 01

Isosorbide Mononitrate is an extended-release medication manufactured by Heritage, East Brunswick, NJ. The NDC number and the Source NDC number are 70518-2122-01 and 23155-0519-05, respectively. The Lot # and the expiration date are not available. The medication should be stored in a cool and dry place away from children’s reach. The directions for use are mentioned in the package insert. The medication is repackaged by RemedyRepack Inc. located in Indiana, PA.*

Remedy_Label - Remedy Label

Remedy_Label - Remedy Label

Isosorbide Mononitrate is an extended-release medication produced by Heritage. Its purpose is not clear from the provided text. The package comes with a direction for use, which is detailed on the insert. RemedyRepack Inc. has repackaged the product. The medication should be stored at a temperature between 20-26°C or 63-77°F with excursions allowed between 15-30°C or 59-86°F. The expiry date and lot number are not available in the provided text. The medication should be kept out of the reach of children.*

structural formula

structural formula

table 1

table 1

This text seems to be presenting results from single and multiple-dose studies involving extended-release tablets of a drug called ISMN. The text includes measurements of AUC (area under the curve), concentration (in Cong/ml), and CU/F (cumulative urinary recovery of unchanged drug over time). There are also indications of different dosages of the tablets (60 mg, 120 mg) evaluated. Unfortunately, there seems to be missing information that could provide more context and clarity for these findings.*

table 2

table 2

This is a data table presenting frequency of adverse events in three controlled North American studies related to different doses of a medication. The adverse events include headache and dizziness, and the percentage of patients experiencing these events at different dosages is shown. Patients were started on 60mg and titrated to their final dose.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.